The higher expression of the CSF1R:CSF1 pair in the M-H subgroup is consistent with the M2 macrophage enrichment in this subtype and nominates a therapeutically actionable immune checkpoint axis for future translational studies guided by matrisome-based stratification of GBM patients. This evidence concerns the gene CSF1 and glioblastoma.